Restenosis after endovascular revascularization in peripheral artery disease

Area of Science:

• Vascular Surgery
• Interventional Cardiology
• Biomedical Engineering

Background:

• Endovascular revascularization (EVR) is a primary treatment for peripheral artery disease (PAD).
• High acute success rates are achieved, but restenosis limits long-term efficacy.
• Outcomes vary significantly by anatomical location and lesion characteristics.

Purpose of the Study:

• To review the mechanisms of restenosis after EVR.
• To evaluate current EVR options and their impact on restenosis rates.
• To highlight advancements in managing PAD.

Main Methods:

• Literature review of endovascular revascularization techniques for PAD.
• Analysis of factors influencing restenosis rates (patient comorbidities, lesion morphology, devices).
• Evaluation of outcomes associated with percutaneous transluminal angioplasty, stenting, drug-coated balloons, and drug-eluting stents.

Main Results:

• EVR demonstrates excellent acute success (>95%) across all territories and TASC lesions.
• Restenosis is a major limitation, particularly in infrapopliteal segments.
• Drug-coated balloons and drug-eluting stents have improved primary patency rates, especially in femoropopliteal disease.

Conclusions:

• Restenosis remains a critical challenge in EVR for PAD.
• Technological advancements, including drug-eluting devices, are crucial for improving long-term patency.
• Further research into optimizing EVR strategies is warranted to address segment-specific outcomes.